Diabetes News
New Report Series from Decision Resources Combines Patient-Level Data and Primary Research to Provide Insight into Physician Prescribing Habits
WALTHAM, Mass., Dec. 13 (PRNewswire) - Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that fixed-dose combinations have the highest potential of antidiabetic drugs to increase their first-line usage in the treatment of type 2 diabetes. According to the new report entitled Treatment Algorithm Insight Series: Type 2 Diabetes, fixed-dose combinations such as Avandamet from GlaxoSmithKline, Actoplus Met from Takeda, and Avandaryl from GlaxoSmithKline, which combine metformin and/or sulfonylureas with agents typically used as second-line therapies, feature the same clinical advantages of the leading first-line drugs with the added benefits of convenience for the patient and improved efficacy.
"The higher cost of the combination agents will be offset by their improved efficacy, which we believe physicians will desire in first-line therapies as they become more aggressive in treating type 2 diabetes," said Alice von Loesecke, senior director at Decision Resources.
The new report series from Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to provide exceptional insight into physicians' actual prescribing trends and drivers of product choice from diagnosis through multiple courses of treatment for a specific disease. The Treatment Algorithm Insight Series examines physicians' actual prescribing behavior as they initiate therapy and move through second and third-line choices.